» Articles » PMID: 33489328

Clinical Analysis of Castleman's Disease of the Lacrimal Gland

Overview
Journal J Ophthalmol
Publisher Wiley
Specialty Ophthalmology
Date 2021 Jan 25
PMID 33489328
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the clinical manifestations, imaging characteristics, and pathological characteristics of Castleman's disease of the lacrimal gland, enhance the knowledge of the disease, and improve the level of its diagnosis and treatment.

Methods: In the retrospective study, the data of 5 patients diagnosed with Castleman's disease of the lacrimal gland in Tianjin Medical University Eye Hospital from 2014 to 2018 were analyzed, and the relevant literature was reviewed.

Results: All the 5 patients were confirmed by pathological examination. Clinical manifestations were characterized by mass occupying lesions in the lacrimal gland area, without obvious pain, accompanied by eyelid swelling and ptosis, as well as space-occupying symptoms. Imaging examination showed that there was a soft tissue mass in the enlarged lacrimal gland area, and the mass was rich in blood flows while showing no obvious specificity, which could invade the surrounding muscles. All patients underwent surgical resection. Pathological results showed that 1 case was of the hyaline-vascular type, 3 cases were of the plasma cell type, and 1 case showed malignant transformation to plasma cell tumor.

Conclusion: Castleman's disease of the lacrimal gland is a rare orbital lymphoproliferative disease lacking specificity in clinical manifestations and imaging examination. As there are difficulties in differentiating the disease from orbital inflammatory pseudotumor and orbital lymphoma, its diagnosis still depends on pathological examination. The disease is mainly treated with surgical resection, and the pathological type is determined postoperatively.

Citing Articles

Plasma cell type Castleman's disease of lacrimal gland: a case report and literature review.

Xu L, Li J, Xu X, Ren T, Ma J BMC Ophthalmol. 2024; 24(1):508.

PMID: 39587531 PMC: 11587699. DOI: 10.1186/s12886-024-03775-1.


A Rare Case of Orbital Castleman Disease with Overlapping IgG4-Related Disease.

Liu L, Chen Y, Liu N, Chen Y, Chien K Medicina (Kaunas). 2023; 59(8).

PMID: 37629670 PMC: 10456907. DOI: 10.3390/medicina59081381.


Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report.

Kosmidis C, Mystakidou C, Koimtzis G, Papadopoulou E, Theodorou V, Katsios N Medicina (Kaunas). 2022; 58(9).

PMID: 36143899 PMC: 9505402. DOI: 10.3390/medicina58091222.

References
1.
Wang S, Hu Q, Liu S . [Report of a case with multicentric Castleman's disease associated with EB virus infection]. Zhonghua Er Ke Za Zhi. 2016; 54(1):69-70. DOI: 10.3760/cma.j.issn.0578-1310.2016.01.018. View

2.
Kang D, Lee J, Lee H, Baek S . Unicentric Castleman's disease in the orbit: A case report. Indian J Ophthalmol. 2015; 63(6):555-7. PMC: 4550999. DOI: 10.4103/0301-4738.162645. View

3.
Liu D, Shields J, Li C, Ng H, Lam D . Hypertensive choroidopathy in Castleman's disease. Graefes Arch Clin Exp Ophthalmol. 2011; 249(12):1901-3. DOI: 10.1007/s00417-011-1721-x. View

4.
Goto H, Takahira M, Azumi A . Erratum to: Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015; 59(3):201. DOI: 10.1007/s10384-015-0376-2. View

5.
Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T . Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 1999; 95(1):56-61. View